New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing from the LSP Health Economics Fund 2, in series D2 fundraise Use of proceeds [...]

If joining a truly innovative medtech company may be part of your end-of-year resolutions, we have good news for you: Xeltis is hiring! We are expanding our device development and clinical trial programs and [...]

The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh, at the Polymers in Medicine and Biology Workshop, Napa (CA - USA) on Wednesday 30 [...]

Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in New York City this Saturday. In a session on new technologies for vascular access [...]

Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular graft, discussed the study and the significant potential held by Xeltis’ technology in dialysis [...]

Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have been successfully implanted, as part of the AXESS European pivotal trial at AZ Sint-Jan [...]

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device, potentially superior to saphenous veins. It is the most prolonged patency ever demonstrated for [...]

Xeltis’ restorative pulmonary heart valve is featuring at the prestigious Pulmonary Heart Valve Global Multidisciplinary Workshop organized by the US Food and Drug Administration (FDA) in conjunction with the Heart Valve Collaboratory on October 14 [...]